Practical Consultations: Multiple Sclerosis

ABSTRACT

People with multiple sclerosis (MS) are increasingly referred for specialty care to tertiary centers, particularly for advice regarding initiation and monitoring of immunomodulatory therapies. However, the generalist must still be able to apply appropriate skills and technology to diagnose the disease and its complications, provide basic counseling of patients, and be aware of potential treatment options at the time of diagnosis and when therapeutic regimens fail. A general approach, supported by evidence where possible, to common and contemporary clinical issues in MS care is provided in a case-based narrative.

KEYWORDS

Multiple sclerosis - clinically isolated syndrome - immunomodulating therapies

REFERENCES

• 1 Morrissey S P, Miller D H, Kendall B E. et al . The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study.  Brain . 1993;  116 135-146
• 2 O'Riordan J I, Thompson A J, Kingsley D P. et al . The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up.  Brain . 1998;  121 495-503
• 3 Brex P A, Ciccarelli O, O'Riordan J I, Sailer M, Thompson A J, Miller D H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.  N Engl J Med . 2002;  346 158-164
• 4 Poser C M, Paty D W, Scheinberg L C. et al . New diagnostic criteria for multiple sclerosis: guidelines for research protocols.  Ann Neurol . 1983;  13 227-231
• 5 McDonald W I, Compston A, Edan G. et al . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.  Ann Neurol . 2001;  50 121-127
• 6 Barkhof F, Filippi M, Miller D H. et al . Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis.  Brain . 1997;  120 2059-2069
• 7 Tintoré M, Rovira A, Martinez M. et al . Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.  AJNR . 2000;  21 702-706
• 8 Dalton C M, Brex P A, Miszkiel K A. et al . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis.  Ann Neurol . 2002;  52 47-53
• 9 Tintoré M, Rovira A, Rio J. et al . New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.  Neurology . 2003;  60 27-30
• 10 Brex P A, Miszkiel K A, O'Riordan J I. et al . Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow-up MRI.  J Neurol Neurosurg Psychiatry . 2001;  70 390-393
• 11 Berger T, Rubner P, Schautzer F. et al . Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.  N Engl J Med . 2003;  349 139-145
• 12 Noseworthy J N, Lucchinetti C F, Rodriguez M, Weinshenker B G. Multiple sclerosis.  N Engl J Med . 2000;  343 938-952
• 13 Thompson A J, Montalban X, Barkhof F. et al . Diagnostic criteria for primary progressive multiple sclerosis: a position paper.  Ann Neurol . 2000;  47 831-835
• 14 Jacobs L D, Beck R W, Simon J H. et al . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.  N Engl J Med . 2000;  343 898-904
• 15 Comi G, Filippi M, Barkhof F. et al . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet . 2001;  357 1576-1582
• 16 O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis.  Neurology . 2002;  59(Sl3) S1-S33
• 17 Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis.  N Engl J Med . 2000;  343 1430-1438
• 18 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology . 1993;  43 655-661
• 19 Johnson K, Brooks B, Cohen J. et al . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.  Neurology . 1995;  45 1268-1276
• 20 Jacobs L D, Cookfair D L, Rudick R A. et al . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol . 1996;  39 285-294
• 21 PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.  Lancet . 1998;  352 1498-1504
• 22 Comi G, Filippi M, Wolinsky J, and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis.  Ann Neurol . 2001;  49 290-297
• 23 Stone L A, Frank J A, Albert P S. et al . The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.  Ann Neurol . 1995;  37 611-619
• 24 Li D KB, Paty D W. and the UBC MS/MRI Analysis Research Group and PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis.  Ann Neurol . 1999;  46 197-206
• 25 IFNB Multiple Sclerosis Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years.  Neurology . 1996;  47 889-894
• 26 PRISMS Study Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS.  Neurology . 2001;  56 1628-1636
• 27 Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.  Arch Neurol . 2001;  58 1297-1298
• 28 Paty D W, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFNβ-1: the use of an assay for neutralizing antibody.  Neurology . 1996;  47 865-866
• 29 Panitch H, Goodin D S, Francis G. for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group et al Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial.  Neurology . 2002;  59 1496-1506
• 30 Durelli L, Verdun E, Barbero P. et al . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).  Lancet . 2002;  359 1453-1460
• 31 Clanet M, Radue E W, Kappos L. et al . A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS.  Neurology . 2002;  59 1507-1517
• 32 Khan O A, Dhib-Jalbut S S. Neutralizing antibodies to interferon β-1a and interferon β-1b in MS patients are cross-reactive.  Neurology . 1998;  51 1698-1702
• 33 Markovic-Plese S, Bielekova B, Kadom N. et al . Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon β-1b.  Neurology . 2003;  60 1849-1851
• 34 Gobbini M I, Smith M E, Richert N D, Frank J A, McFarland H F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.  J Neuroimmunol . 1999;  99 142-149
• 35 Patti F, Cataldi M L, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis.  J Neurol Neurosurg Psychiatry . 2001;  71 404-407
• 36 Lublin F, Baier M, Cutter G. et al . Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate.  Neurology . 2002;  58 (suppl 3) A85
• 37 Herndon R M. Why secondary progressive multiple sclerosis is a relentlessly progressive disease.  Arch Neurol . 2002;  59 301-304
• 38 European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis.  Lancet . 1998;  352 1491-1497
• 39 Kappos L, and the European Study Group on Interferon β1b. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS.  Neurology . 2001;  57 1969-1975
• 40 Goodkin D. and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial (abstract).  Neurology . 2000;  54 2352
• 41 Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS.  Neurology . 2001;  56 1496-1504
• 42 Cohen J A, Cutter G R, Fischer J S, for the IMPACT Investigators. et al . Benefit of interferon β-1a on MSFC progression in secondary progressive MS.  Neurology . 2002;  59 679-687
• 43 Bornstein M B, Miller A, Slagle S. et al . A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis.  Neurology . 1991;  41 533-539
• 44 Hartung H P, and the Mitoxantrone in Multiple Sclerosis Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.  Lancet . 2002;  360 2018-2025
• 45 Durelli L, Cocito D, Riccio A. et al . High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations.  Neurology . 1986;  36 238-243
• 46 Milligan N M, Newcombe R, Compston D A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects.  J Neurol Neurosurg Psychiatry . 1987;  50 511-516
• 47 Alam S M, Kyriakides T, Lawden P K, Newman P K. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.  J Neurol Neurosurg Psychiatry . 1993;  56 1219-1220
• 48 Barnes D, Hughes R, Morris R. et al . Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.  Lancet . 1997;  349 902-906
• 49 Millar J HD, Vas C J, Noronha M J. et al . Long-term treatment of multiple sclerosis with corticotropin.  Lancet . 1967;  2 429-431
• 50 Weinshenker B G, O'Brien P, Petterson T. et al . A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease.  Ann Neurol . 1999;  46 878-886
• 51 Keegan M, Pineda A A, McClelland R L. et al . Plasma exchange for severe attacks of CNS demyelination: predictors of response.  Neurology . 2002;  58 143-146
• 52 Sibley W A, Bamford C R, Clark K. Clinical viral infections and multiple sclerosis.  Lancet . 1985;  1 1313-1315
• 53 Walther E U, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management.  Neurology . 1999;  53 1622-1627
• 54 Confavreux C, Hutchinson M, Hours M M. et al . Rate of pregnancy-related relapse in multiple sclerosis.  N Engl J Med . 1998;  339 285-291
• 55 Damek D M, Shuster E A. Pregnancy and multiple sclerosis.  Mayo Clin Proc . 1997;  72 977-989
• 56 Sicotte N L, Liva S M, Klutch R. et al . Treatment of multiple sclerosis with the pregnancy hormone estriol.  Ann Neurol . 2002;  52 421-428
• 57 Sadovnick A D, Ebers G C. Genetics of multiple sclerosis.  Neurol Clin . 1995;  13 99-118
• 58 Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, Ebers GC, Lassman H, et al, eds. McAlpine's Multiple Sclerosis 3rd ed. London: Churchill Livingstone 1998: 101-190
• 59 Ebers G C, Sadovnick A D, Risch N J. A genetic basis for familial aggregation in multiple sclerosis.  Nature . 1995;  377 150-151
• 60 Sadovnick A D, Dircks A, Ebers G C. Genetic counseling in multiple sclerosis: risk to sibs and children of affected individuals.  Clin Genet . 1999;  56 118-122